Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734833 | 0.84 | GAA (0.56) | GAABCL9CTNNB1PKMKMT2A | |
| P-Nitrophenol SCHEMBL6226065 | 0.80 | GAA (0.51) | GAABCL9CTNNB1PKMKMT2A | |
| SCHEMBL26343991 | 0.78 | ELANE (0.53) | ELANEGAAKMT2A | |
| SCHEMBL2651602 | 0.76 | ELANE (0.45) | ELANEGAAKIF11KMT2AALDH1A1 | |
| SCHEMBL9872338 | 0.75 | LMNA (0.57) | ELANEGAAKMT2AALDH1A1 | |
| SCHEMBL14520259 | 0.75 | GAA (0.41) | GAABCL9CTNNB1PKMKMT2A | |
| SCHEMBL10738024 | 0.75 | ELANE (0.56) | ELANEKMT2ASMN1; SMN2 | |
| SCHEMBL8538472 | 0.75 | ELANE (0.44) | ELANEKIF11KMT2AALDH1A1 | |
| SCHEMBL326469 | 0.75 | ELANE (0.44) | ELANEKIF11 | |
| SCHEMBL27746984 | 0.75 | ELANE (0.48) | ELANEGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408075-B1 | Synthesis of phosphocholine ester derivatives and conjugates thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080175852-A1 | SYNTHESIS OF PHOSPHOCHOLINE ESTER DERIVATIVES AND CONJUGATES THEREOF | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175852-A1 | SYNTHESIS OF PHOSPHOCHOLINE ESTER DERIVATIVES AND CONJUGATES THEREOF | PHOSPHO1, SGMS1, SGMS2 | ELANE 617/4885GAA 2850/4885BCL9 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.